Bain Capital Life Sciences Investors, LLC's Form 4 filing
Kailera Therapeutics, Inc. (KLRA) · filed Apr 20, 2026
- Accession no.
- 0001193125-26-164389
- Filed
- Apr 20, 2026, 6:01 PM ET
- Trade date
- Apr 20, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market purchases total $25.0M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bain Capital Life Sciences Investors, LLCCIK 0001703031 | 10% Owner |
| Bain Capital Life Sciences IV General Partner, LLCCIK 0001996931 | 10% Owner |
| Bain Capital Life Sciences Fund IV, L.P.CIK 0001996979 | 10% Owner |
| BCLS Fund IV Investments, L.P.CIK 0002015454 | 10% Owner |
| BCLS Fund IV Investments GP, LLCCIK 0002015967 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 20, 2026 | Common Stock | CConversionAcquired | +16,875,000 | –F1 | – | 16,875,000 | Indirect | Duplicate filing |
| Apr 20, 2026 | Common Stock | CConversionAcquired | +4,145,768 | –F2 | – | 21,020,768 | Indirect | Duplicate filing |
| Apr 20, 2026 | Common Stock | PPurchaseAcquired | +1,562,500 | $16.00 | +$25,000,000 | 22,583,268 | Indirect | Duplicate filing |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 20, 2026 | Common Stock | CConversionDisposed | −16,875,000 | $0.00 | $0 | 0 | Indirect | Duplicate filing |
| Apr 20, 2026 | Common Stock | CConversionDisposed | −4,145,768 | $0.00 | $0 | 0 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
Referenced by the price of 1 transaction in Table I.
- F2
Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
Referenced by the price of 1 transaction in Table I.